Pharmaceutical Companies

The oral drug was being evaluated in adults with MSA, a rare and progressive neurodegenerative disorder that affects movement, coordination and balance.

The collaboration will initially focus on biosimilar versions of Roche’s cancer treatment Polivy and Amgen’s thyroid eye disease therapy Tepezza.

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the expanded indication, lowering the minimum eligible age from 12 to five years for both conditions.

Lonza also plans to introduce 500-litre single-use manufacturing capacity across its existing mid-scale bioconjugation facilities from 2027.

AstraZeneca plans to reinvest most of the savings in research and development, although the programme is expected to incur up to US$2 billion in one-time restructuring costs over three years.

The clinical-stage biotechnology company will also use the proceeds to expand its research pipeline across autoimmune diseases, immunology, neurological disorders and oncology.

The new sterile manufacturing plant will complement Bracco’s existing production operations in Europe, Asia and Canada, expanding its global manufacturing network.

The facility operates in accordance with requirements established by the US Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

Operated by OMRON HEALTHCARE MANUFACTURING INDIA Pvt. Ltd., the approximately 24,000-square-metre factory is located at ORIGINS by Mahindra and has five production lines serving the Indian market.

The financing attracted existing investors Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures.